Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rettig

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Nature Medicine|November 9, 2010
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceHiroshi Tanaka, Evelyn Kono, Chau P Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2018
Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate CancerJeremie Calais, Amar U Kishan, Minsong Cao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter StudyAndrei Gafita, Isabel Rauscher, Manuel Weber, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
JAMA Network Open|May 12, 2025
Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate CancerLuca F Valle, Jiannong Li, Heena Desai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2025
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective studyLena M Unterrainer, Andrea Farolfi, Tristan Grogan, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADARWee Loon Ong, John Nikitas, David Joseph, et al.
Cancer Research|May 17, 2020
Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617: A Single-Center Retrospective StudyVishnu Murthy, Koichiro Kimura, Lela Theus, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Nature Medicine|November 9, 2010
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceHiroshi Tanaka, Evelyn Kono, Chau P Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2018
Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate CancerJeremie Calais, Amar U Kishan, Minsong Cao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter StudyAndrei Gafita, Isabel Rauscher, Manuel Weber, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
JAMA Network Open|May 12, 2025
Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate CancerLuca F Valle, Jiannong Li, Heena Desai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2025
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective studyLena M Unterrainer, Andrea Farolfi, Tristan Grogan, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADARWee Loon Ong, John Nikitas, David Joseph, et al.
Cancer Research|May 17, 2020
Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617: A Single-Center Retrospective StudyVishnu Murthy, Koichiro Kimura, Lela Theus, et al.
Pageof 15